Short Interest in Omnicell, Inc. (NASDAQ:OMCL) Grows By 34.8%

Omnicell, Inc. (NASDAQ:OMCL) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 2,210,000 shares, a growth of 34.8% from the March 15th total of 1,640,000 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average trading volume of 523,600 shares, the days-to-cover ratio is currently 4.2 days.

Omnicell Stock Down 2.2 %

Shares of NASDAQ:OMCL traded down $0.67 during mid-day trading on Friday, hitting $30.28. 727,408 shares of the company traded hands, compared to its average volume of 533,669. The firm has a market cap of $1.42 billion, a P/E ratio of 112.15, a PEG ratio of 7.53 and a beta of 0.78. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.75. The firm’s 50 day simple moving average is $35.27 and its 200 day simple moving average is $41.27. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts anticipate that Omnicell will post 1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Tuesday, April 15th. Benchmark reaffirmed a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. decreased their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Finally, Wells Fargo & Company cut their price objective on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Thursday. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $50.67.

Institutional Trading of Omnicell

Several large investors have recently modified their holdings of OMCL. Accurate Wealth Management LLC increased its holdings in Omnicell by 27.4% in the first quarter. Accurate Wealth Management LLC now owns 36,131 shares of the company’s stock valued at $1,263,000 after buying an additional 7,762 shares during the last quarter. Bridge City Capital LLC lifted its position in shares of Omnicell by 1.6% in the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company’s stock worth $1,403,000 after buying an additional 650 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Omnicell by 2,892.5% in the 1st quarter. GAMMA Investing LLC now owns 43,211 shares of the company’s stock valued at $1,511,000 after buying an additional 41,767 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Omnicell by 22.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company’s stock worth $5,306,000 after acquiring an additional 21,847 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in Omnicell by 286.4% in the fourth quarter. Squarepoint Ops LLC now owns 149,717 shares of the company’s stock worth $6,665,000 after acquiring an additional 110,966 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.